Neelam Goyal, MD
Neurology · Stanford, CANPI 1558500256
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $175,496 of the $270,359 with a category attached, or 64.9%. 11 manufacturers reported payments, led by UCB, Inc. at 26.4% of the total. 2025 is the largest year on record at $90,494, more than ten times the $6,884 reported in 2019. Among neurology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 266 payments — averaging $1016.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$71K
- AstraZeneca$67K
- Argenx US, Inc.$32K
- Amgen$30K
- Johnson & Johnson$26K
- Janssen Scientific Affairs, LLC$13K
- plus $31K from 5 others
Across 43 payments — averaging $7296.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$111K
- Takeda Pharmaceuticals U.S.A., Inc.$99K
- Argenx US, Inc.$66K
- UCB SA$37K
What the payments were for
- Consulting fees$175,49665%
- Speaking & faculty fees$65,14024%
- Travel & lodging$22,6698%
- Food & beverage$6,9443%
- Education$1100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 59 | $71,384 |
| AstraZeneca | 60 | $67,353 |
| Argenx US, Inc. | 48 | $31,619 |
| Amgen | 29 | $29,911 |
| Johnson & Johnson(2 entities) | 22 | $26,463 |
| Janssen Scientific Affairs, LLC | 12 | $12,838 |
| Merck Kgaa | 7 | $10,050 |
| Janssen Global Services, LLC | 9 | $7,244 |
| UCB SA | 11 | $5,282 |
| CSL Behring | 8 | $5,177 |
| Novartis Pharma AG | 1 | $3,038 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$270,359 in reported general payments places this provider in the 95th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 48 | $684,518 |
| Mycophenolate Mofetil | 113 | $30,091 |
| Pyridostigmine Bromide | 54 | $3,899 |
| Azathioprine | 16 | $3,053 |
| Prednisone | 124 | $777 |
| Gabapentin | 28 | $725 |
| MethotrexateMethotrexate Sodium | 27 | $518 |
| Duloxetine Hcl | 20 | $137 |
Paid to pharmacies, not to this prescriber.
Other neurology in Stanford
- Jeffrey DunnStanford$437K
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
- David LiebeskindLos Angeles$1.9M
- Jack SchimCarlsbad$1.7M
- Parshaw DorrizMission Viejo$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.